Edition:
United States

Silence Therapeutics PLC (SLN.L)

SLN.L on London Stock Exchange

143.00GBp
18 Aug 2017
Change (% chg)

1.50 (+1.06%)
Prev Close
141.50
Open
140.00
Day's High
144.75
Day's Low
140.00
Volume
42,645
Avg. Vol
44,143
52-wk High
149.75
52-wk Low
71.88

SLN.L

Chart for SLN.L

About

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a... (more)
No analyst recommendations are available for SLN.L.

Overall

Beta: 0.95
Market Cap(Mil.): £100.09
Shares Outstanding(Mil.): 69.99
Dividend: --
Yield (%): --

Financials

  SLN.L Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -0.12 -- --
ROI: -14.73 2.83 14.89
ROE: -14.73 5.09 16.13

BRIEF-Silence Therapeutics licensee Quark announces positive AKI results

* NOTES QUARK PHARMACEUTICAL PRESS RELEASE WHICH REPORTS POSITIVE RESULTS FROM PHASE 2 STUDY

Jul 27 2017

BRIEF-Silence Therapeutics says ‍CEO Ali Mortazavi appointed non-executive chairman of Ultromics

* Says ‍CEO Ali Mortazavi has been appointed as non-executive chairman of Ultromics with immediate effect​ Source text: http://bit.ly/2tPOoWz Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Jul 14 2017

Earnings vs. Estimates